ALEJANDRO HERNÁNDEZ MARTINEZ

Projectes

Precision Oncology in Girona

Estudio descriptivo y efecto del ritmo circadiano en el tratamiento con quimio-inmunoterapia neoadyuvante del cáncer del pulmón de célula no pequeña en estadios precoces. Un estudio multicéntrico con resultados de Real World Data (RWD)

Codi oficial: 2024_GECP_CMF Start date:01/12/2024 Data fi: 30/11/2026 Investigador/a principal: CLAUDIA MONTAÑES FERRER Organisme finançador: GRUPO ESPAÑOL DE CANCER DE PULMON

Publicacions

Precision Oncology in Girona , Cardiovascular Genetics , Medical Imaging

Sabaté-Ortega, J, Teixidor-Vilà, E, Sais, E, Hernandez-Martínez, A, Montañés-Ferrer, C, Coma, N, Polonio-Alcalá, E, Pineda, V, Bosch-Barrera, J

Cardiovascular toxicity induced by immunotherapy in non-small cell lung cancer: a systematic review and meta-analysis of observational studies

Frontiers in oncology, 2025, 15 dx.doi.org/10.3389/fonc.2025.1528950

Descriptive epidemiology, genetics and cancer prevention , Precision Oncology in Girona , Metabolism and Cancer

Teixidor-Vilà E, Trallero J, Puigdemont M, Vidal-Vila A, Hernandez-Martínez A, Sais E, Sabaté-Ortega J, Verdura S, Menendez JA, Bosch-Barrera J, Sanvisens A, Marcos-Gragera R

Lung cancer survival trends and prognostic factors: A 26-year population-based study in Girona Province, Spain.

LUNG CANCER, 2024, 197, 107995-107995 dx.doi.org/10.1016/j.lungcan.2024.107995

Precision Oncology in Girona , Radiation Oncology and Medical Physics of Girona

Sais, E, PLUJA CASTELLANO, ANNA, MONTAÑES FERRER, CLAUDIA, Bujons-Buscarons, E, PINEDA RIVERO, FRANCISCO JAVIER, Iguaran A, Roselló À, Hernández Martínez A, Teixidor-Vilà, E, ROMERA, ALVARO, Bosch-Barrera, J, ERASO URIÉN, ARANTXA, Oliva-Poch E

1062P Effect of the immunological circadian rhythm on the treatment of locally advanced non-small cell lung cancer treated with consolidation immunotherapy

ANNALS OF ONCOLOGY, 2024, 35, 1-1 dx.doi.org/10.1016/j.annonc.2024.08.1120

Precision Oncology in Girona , Metabolism and Cancer

Teixidor-Vilà, E, Verdura, S, JA Encinar, Llop-Hernández À, Sais, E, Hernández Martínez A, ROMERA, A., Brunet JM, Martin-Castillo B, Lopez-Bonet, E, Bosch-Barrera, J, Cuyàs, E, Menendez, JA

1039P Discovery of a novel inhibitor of PD-L1 maturation that overcomes adaptive resistance to cancer immunotherapy

ANNALS OF ONCOLOGY, 2024, 35, 697-697 dx.doi.org/10.1016/j.annonc.2024.08.1097

Precision Oncology in Girona , Metabolism and Cancer

Teixidor E, Sais E, Vásquez CA, Carbajal W, Hernández A, Sánchez G, Izquierdo A, Verdura S, Menéndez JA, Bosch-Barrera J

Addendum: Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.

Oncotarget, 2023, 14, 668-668 dx.doi.org/10.18632/oncotarget.28471

Descriptive epidemiology, genetics and cancer prevention , Precision Oncology in Girona , Medical Imaging , Metabolism and Cancer , Haematology

Bosch-Barrera, J, Teixidor, E, Sanvisens, A, Puigdemont, M, Trallero, J, Vila, AV, Osca, G, Roberte, MV, Priego, N, Sais, E, Martínez, AH, Ortega, JS, Cuyàs, E, Verdura, S, Puig, J, Pineda, V, Martí-Navas, M, Calvo, A, Menendez, JA, Marcos-Gragera, R, Valiente, M

Using Silibinin to Target STAT3-Positive Reactive Astrocytes for the Treatment of NSCLC Brain Metastases

JOURNAL OF THORACIC ONCOLOGY, 2023, 18, 426-427

Metabolism and Cancer , Precision Oncology in Girona

Monteiro C, Miarka L, Perea-García M, Priego N, García-Gómez P, Álvaro-Espinosa L, de Pablos-Aragoneses A, Yebra N, Retana D, Baena P, Fustero-Torre C, Graña-Castro O, Troulé K, Caleiras E, Tezanos P, Muela P, Cintado E, Trejo JL, Sepúlveda JM, González-León P, Jiménez-Roldán L, Moreno LM, Esteban O, Pérez-Núñez Á, Hernández-Lain A, Mazarico Gallego J, Ferrer I, Suárez R, Garrido-Martín EM, Paz-Ares L, Dalmasso C, Cohen-Jonathan Moyal E, Siegfried A, Hegarty A, Keelan S, Varešlija D, Young LS, Mohme M, Goy Y, Wikman H, Fernández-Alén J, Blasco G, Alcázar L, Cabañuz C, Grivennikov SI, Ianus A, Shemesh N, Faria CC, Lee R, Lorigan P, Le Rhun E, Weller M, Soffietti R, Bertero L, Ricardi U, Bosch-Barrera J, Sais E, Teixidor E, Hernández-Martínez A, Calvo A, Aristu J, Martin SM, Gonzalez A, Adler O, Erez N, RENACER, Valiente M

Stratification of radiosensitive brain metastases based on an actionable S100A9/RAGE resistance mechanism

NATURE MEDICINE, 2022, 28, 752-765 dx.doi.org/10.1038/s41591-022-01749-8

Metabolism and Cancer , Descriptive epidemiology, genetics and cancer prevention , Precision Oncology in Girona

Bosch-Barrera J, Verdura S, Ruffinelli JC, Carcereny E, Sais E, Cuyàs E, Palmero R, Lopez-Bonet E, Hernández-Martínez A, Oliveras G, Buxó M, Izquierdo A, Morán T, Nadal E, Menendez JA

Silibinin Suppresses Tumor Cell-Intrinsic Resistance to Nintedanib and Enhances Its Clinical Activity in Lung Cancer

Cancers, 2021, 13 dx.doi.org/10.3390/cancers13164168

Precision Oncology in Girona

Palomeras S, Diaz-Lagares Á, Viñas G, Setien F, Ferreira HJ, Oliveras G, Crujeiras AB, Hernández A, Lum DH, Welm AL, Esteller M, Puig T

Epigenetic silencing of TGFBI confers resistance to trastuzumab in human breast cancer

BREAST CANCER RESEARCH, 2019, 21, 79-79 dx.doi.org/10.1186/s13058-019-1160-x

Metabolism and Cancer , Precision Oncology in Girona

López Brunsó M, Toro Blanch C, Sais Girona E, Roa García D, Hernández Martínez A, Izquierdo Font A, Guerra Prió S, Mas Pueyo HG, Bosch-Barrera J

Probable drug-drug interaction between erlotinib and amiodarone causes severe neurotoxicity in a patient with advanced lung cancer

ANTI-CANCER DRUGS, 2018, 29, 380-383 dx.doi.org/10.1097/CAD.0000000000000600

Directori